Summit reports consistent OS benefit for ivonescimab in HARMONi; HARMONi-2 OS data positive

Summit Therapeutics Inc.

Updated HARMONi OS analysis: global ITT HR 0.76 (95% CI 0.61-0.95; p=0.0151), median OS 16.8 vs 14.0 months.
Western subgroup OS HR 0.76 (95% CI 0.52-1.10), consistent with global; median follow-up 23.2 months.
HARMONi-2 (Akeso-sponsored) OS: HR 0.73 (95% CI 0.57-0.95; p=0.009) vs pembrolizumab; median OS 30.8 vs 22.6 months.
No new safety signals; BLA PDUFA date for ivonescimab is November 14, 2026.

Featured in Daily 8-K Digest

Selected #10 for 2026-09-15. Read digest

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.